Description:
Reference #: 01645
The University of South Carolina is offering licensing opportunities for An Amino Acid Hybrid of a CGRP to Treat Cardiovascular Disease.
Background:
Heart failure is a chronic condition affecting millions of people worldwide, often leading to reduced lifespan and poor quality of life. The American Heart Association (AHA) estimates that by 2035, 45.1% of the US population would have some form of cardiovascular disease (CVD). This predicted growth only heightens the already pervasive need for successful CVD treatments.
Invention Description:
In this breakthrough innovation, researchers have created a hybrid peptide that acts as a powerful vasodilator, effectively widening blood vessels and improving blood flow. By modifying the Alpha-calcitonin gene related peptide (CGRP), they have achieved a compound that exhibits no toxicity and lowers blood pressure comparable to the natural peptide. This innovative development has the potential to significantly extend the lifespan of individuals battling heart failure, offering new hope and improved treatment options. The researchers plan to administer the hybrid CGRP peptide subcutaneously and monitor its effects on blood pressure in mice, confirming its biological activity in vivo. If successful, this novel drug technology has the potential to revolutionize existing therapies for treating heart failure, offering improved stability and efficacy.
Potential Applications:
This innovation addresses the challenge of the short half-life of the native CGRP peptide in the body, which limits its therapeutic potential. By modifying the peptide with naturally occurring amino acids, the innovation ensures prolonged stability and protection against degradation. This opens new possibilities for the application of the modified peptide in various medical treatments, potentially benefiting areas such as cardiovascular diseases, hypertension, and myocardial ischemia by harnessing its healing effects for an extended duration.
Advantages and Benefits:
The utilization of an FDA-approved hybrid peptide in this idea offers significant advantages in terms of stability and resistance to degradation, ensuring sustained bioactivity over an extended duration. The simple and cost-effective synthesis procedure enables mass production, making it accessible for widespread use. Additionally, the availability of multiple delivery options enhances its versatility, while the successful publication of a similar approach for enhancing wound healing highlights the potential benefits and efficacy of this innovation in therapeutic applications.